Montpellier-based biotech secures improved royalty terms on its two lead hearing loss programs, CIL001 and CIL003, while Sanofi takes a minority stake in the company.
Cilcare, a biotechnology company focused on developing therapies for hearing disorders, has announced an update to its existing license agreement with Sanofi covering its two lead programs — CIL001 and CIL003 — on substantially improved royalty terms. As part of the revised arrangement, Sanofi will become a minority shareholder in Cilcare.
The renegotiated deal reflects what Cilcare describes as the growing maturity and clinical potential of its pipeline. Under the updated terms, Cilcare receives enhanced royalty conditions in exchange for granting Sanofi a minority equity position — a structure the company says provides long-term strategic value for advancing both candidates in hearing loss.
“Re-imagining our licensing agreement with Sanofi — who will become a minority shareholder — provides strong validation of our scientific strategy and our vision of positioning hearing health as a critical pillar of global health,” says Celia Belline, co-founder and CEO of Cilcare, in a release. “The agreement enhances our ability to accelerate the development of innovative therapies for millions of patients affected by hearing loss worldwide.”
Belline also noted that hearing loss is now recognized as the leading modifiable risk factor for dementia, a designation that the company says reinforces the urgency of addressing hearing disorders as a broader public health priority.
Part of a Broader Pharma Partnership Strategy
The Sanofi update is the latest move in Cilcare’s stated strategy of cultivating long-term relationships with major pharmaceutical partners. It follows the company’s option agreement with Shionogi for hearing disorder treatment and the close of its Series A funding round, which helped advance clinical trials for cochlear synaptopathy.
Headquartered in Montpellier, France, with operations in Boston and Tokyo, Cilcare integrates proprietary multimodal auditory data, biomarkers, and AI-driven analytics to stratify patients at early stages of clinical development — an approach the company says is designed to improve clinical success rates and reduce development risk.
A Growing Global Need
The updated agreement arrives against the backdrop of a rapidly expanding global burden of hearing loss. According to the World Health Organization, more than 1.6 billion people currently live with the condition, a figure projected to reach 2.5 billion by 2050.
Cilcare’s portfolio targets multiple biological mechanisms involved in hearing loss, applying a precision medicine approach to identify patient populations most likely to benefit from its therapeutic candidates. The company’s pipeline spans hearing loss and tinnitus, areas the company views as both sensory disorders and significant comorbidities linked to chronic inflammatory and neurodegenerative diseases.
For more information, visit www.cilcare.com.
